Latest Manufacturing News

Page 12 of 335
Algorae Pharmaceuticals has moved closer to its first expected NSW Health supply orders while reporting stronger preclinical results from its AOS2 drug-discovery platform. The company ended September with $3.15 million in cash and a further $3 million undrawn facility, but its commercial contract carries no minimum volume commitment.
Victor Sage
Victor Sage
30 Oct 2026
Optiscan has moved its InForm and InVue medical-imaging devices into formal US FDA review after a quarter of intensive regulatory and clinical work. The milestone comes with $11.093 million in cash and a reported 3.5 quarters of funding at the latest operating burn rate.
Victor Sage
Victor Sage
30 Oct 2026
Sparc Technologies has moved its graphene additive business from testing towards commercial adoption, with a first ecosparc® delivery to a tier 1 coatings manufacturer and more than 20 active qualification programs. The September quarter also delivered hydrogen progress and fresh funding, but the company reported only 1.14 quarters of cash coverage before subsequent receipts.
Sophie Babbage
Sophie Babbage
30 Oct 2026
Novatti’s AU/NZ quarterly transaction value rose to $1.2 billion, but regulatory disruption to international BPAY payments pushed revenue lower and left Cash EBITDA negative. The company is targeting an early 2027 relaunch while relying on pipeline conversion and product mix improvements to support its next phase of growth.
Claire Turing
Claire Turing
30 Oct 2026
Alexium has lifted production efficiency and September revenue, but ended the quarter with only US$337,000 of cash and available funding. The company remains dependent on further shareholder loans while targeting positive operating cash flow in June 2027.
Victor Sage
Victor Sage
30 Oct 2026
Aurora Labs has moved another step from propulsion development toward commercial production, securing AS9100D certification and its first US engine order while customer enquiries expand. But with only A$1.148 million in cash at quarter-end and 1.5 quarters of funding estimated, the A$6 million raise is central to the next phase.
Victor Sage
Victor Sage
30 Oct 2026
Clever Culture Systems has started FY27 with three APAS Independence sales to Novo Nordisk and AstraZeneca, while targeting eight first-half sales and evaluations. The sales momentum comes with $1.6 million of unsecured loans due in December and a proposed extension still to be secured.
Victor Sage
Victor Sage
30 Oct 2026
The Calmer Co. posted record Q1 FY27 revenue of A$2.44 million, powered by a sharp lift in US wholesale orders and continued Coles and Woolworths growth. But with A$953,000 in cash against quarterly operating outflows of A$755,000, the kava company remains dependent on further funding and sustained sales momentum.
Victor Sage
Victor Sage
30 Oct 2026
Australian Vanadium has moved its flagship project closer to an Optimised Feasibility Study while adding new industrial battery opportunities with Alcoa. But the September quarter also reduced cash to $12.4 million, leaving an estimated 2.5 quarters of funding at the reported spending rate.
Victor Sage
Victor Sage
30 Oct 2026
Environmental Clean Technologies has produced its first MXene on a US Flash Joule Heating reactor, marking a technical step in its defence materials strategy. The harder work now is proving repeatability, performance and customer qualification while building a separate PFAS pilot.
Victor Sage
Victor Sage
30 Oct 2026
DXN has delivered a sharp revenue rebound and lifted its backlog to A$30.8 million, but the growth story is complicated by the expected cancellation of its maiden A$8.8 million AI contract. The company is relying on a new A$12.2 million project, expanding factories and improved customer collections to convert momentum into cash.
Victor Sage
Victor Sage
30 Oct 2026
Swift TV expanded its contracted footprint and qualified pipeline in the September quarter, but ended with $1.047 million in cash and only 0.9 quarters of funding at the reported burn rate. The company is relying on customer receipts, an expected $1.5 million R&D incentive and lending arrangements as commercial deployments accelerate.
Sophie Babbage
Sophie Babbage
30 Oct 2026

Browse the archive

Full archive